TG Therapeutics, Inc.
TG Therapeutics focuses on developing treatments for B-cell mediated diseases. They provide BRIUMVI for relapsing multiple sclerosis treatment. Their pipeline includes Umbralisib for lymphoma and TG-1701/TG-1801, orally available BTK inhibitors. The company has license agreements with LFB Biotechnologies, GTC Biotherapeutics, and others for umbralisib development. They also have a collaboration agreement with Checkpoint Therapeutics for anti-PD-L1 and anti-GITR antibody research programs. TG Therapeutics was incorporated in 1993 and is based in Morrisville, North Carolina. The company has a range of investigational medicines in its research pipeline.
Overview
Strengths
- Consistent growth: revenue has compounded at 426.7% a year over 5 years, rising in 4 of them.
- Paying down debt: long-term debt fell by 19.2 percentage points of total assets last year.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 10.2% in each of the last 6 years.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Our discounted cash flow target price (3.96 USD) is 93% below the current price.
- Unstable profitability: operating margin ranged from -179,996% to 20% over the last 6 years, with operating losses in 3 of them.
- Earnings quality red flag: reported profit exceeds operating cash flow by 44.4% of total assets.
- Margin pressure: gross margin fell 4.6 percentage points last year, pointing to pricing pressure or rising costs.
Key Financial Data